Flawless balance sheet with proven track record
CO delivered a triple-digit bottom-line expansion over the past couple of years, with its most recent earnings level surpassing its average level over the last five years. In addition to beating its historical values, CO also outperformed its industry, which delivered a growth of 9.96%. This is an notable feat for the company.
CO’s strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This indicates that CO has sufficient cash flows and proper cash management in place, which is an important determinant of the company’s health. Looking at CO’s capital structure, the company has no debt on its balance sheet. This implies that the company is running its operations purely on off equity funding. which is typically normal for a small-cap company. Therefore the company has plenty of headroom to grow, and the ability to raise debt should it need to in the future.
For Global Cord Blood, I’ve put together three fundamental factors you should further examine:
- Valuation: What is CO worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether CO is currently mispriced by the market.
- Dividend Income vs Capital Gains: Does CO return gains to shareholders through reinvesting in itself and growing earnings, or redistribute a decent portion of earnings as dividends? Our historical dividend yield visualization quickly tells you what your can expect from CO as an investment.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of CO? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!